Genprex, Inc.
Every calculator, already run for GNPX
Open the full toolkit →You have the numbers on GNPX. Get the argument.
A written report on which of these readings actually decide the outcome for Genprex, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for GNPX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistan…
GNPX — frequently asked
Is GNPX a buy right now?
Wall Street's consensus rating on Genprex, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is GNPX overvalued?
GNPX trades at 0.1x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Genprex, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Genprex, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GNPX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Genprex, Inc., in minutes. 3 free reports included with every account — no credit card required.